Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non-Small-cell Lung Cancer.

Autor: Schneider BJ; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI. Electronic address: bryansch@med.umich.edu., Kalemkerian GP; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI., Gadgeel SM; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI., Valdivieso M; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI., Hackstock DM; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI., Chen W; Biostatistics Core, Karmanos Cancer Institute, Wayne State University, Detroit, MI., Heilbrun LK; Biostatistics Core, Karmanos Cancer Institute, Wayne State University, Detroit, MI., Ruckdeschel JC; Synergy Cancer Center, Las Vegas, NV., Wozniak AJ; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.

Publikováno v: Clinical lung cancer [Clin Lung Cancer] 2017 May; Vol. 18 (3), pp. 299-302. Date of Electronic Publication: 2016 Dec 02.

miR-146a-5p targets TCSF and influences cell growth and apoptosis to repress NSCLC progression.

Autor: Huang, Wen-Ting, He, Rong-Quan, Li, Xiao-Jiao, Ma, Jie, Peng, Zhi-Gang, Zhong, Jin-Cai, Hu, Xiao-Hua, Chen, Gang

Publikováno v: Oncology Reports; Apr2019, Vol. 41 Issue 4, p2226-2240, 15p